BiotechTV
BiotechTV - News
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Be sure to visit the podcast's website and support the creator: podcasters.spotify.com
Author
BiotechTV
Category
Podcast website
Latest episode
Nov 18, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Jefferies London 2026: IDEAYA Biosciences Founder & CEO Yujiro Hata shares an update on darovasertib, which is in front of FDA for Uveal Melanoma, and talks DLL3 and PRMT5 18.11.2026 11:09
He describes the darovasertib filing, which IDEAYA hopes will be for all metastatic uveal melanoma patients. Plus, what makes DLL3 a compelling target, and how interest in PRMT5 has especially taken off given how prevalent MTAP deletions are in pancreatic cancer.
Jefferies London 2026: Forbion, the most active lead investor in private biotech financing rounds globally last year, raised €2.3 billion across two new funds last month 18.11.2026 12:26
Co-Owner and Managing Partner Sander Slootweg discusses the new funds and what kind of companies the funds might be deployed towards. He also shares his ideas and recommendations on how to make Europe more competitive in life sciences and keep companies in the region, and gives his take on the sector's outlook in 2027.
Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution 18.11.2026 13:11
CEO Jason Coloma describes the unmet need in this area - which affects younger people compared to most other chronic kidney conditions. He walks us through MZE829, which just completed enrollment the phase 2 HORIZON trial and will have data in early 2027.
Jefferies London: When Celgene's powerhouse myeloma treatments emerged, it wasn't known that they were protein degraders. With today's advances in science, C4 aims to have a best in class degrader 18.11.2026 12:04
President and CEO Andrew Hirsch describes the concept of protein degraders in general, and the paper that sparked the creation of C4 as a company. He discusses the company's registration intended trial, and another one in combination with a T-cell engager from Pfizer.
Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1 18.11.2026 14:11
He shares his strong belief that for most people taking obesity medicines going forward, tolerability could be the most important factor of choice, which is amylin's strong suit.
Jefferies London 2026: Erasca is racing to be the next big story in the RAS space (in both pancreatic and lung) and believes it may have a best in class asset with high potency 18.11.2026 13:09
CEO Jonathan Lim descrbies the profile of ERAS-0015 and the data the company has derived up to this point. A phase 3 study is planned in 1st line pancreatic cancer in the early part of 2027 and two in lung later in the year. He also discusses combinations, including with Erasca's own KRAS inhibitor.
Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27 18.11.2026 11:42
CEO Sean Bohen reminds us of the mechanism and the design of this monotherapy study, which is in the 2/3 line ER+/HER2 metastatic breast cancer setting. He also discusses why he believes the OPERA-02 study in 2nd line in combo with a CDK 4/6 can succeed where a competitor failed earlier this year.
Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3 17.11.2026 9:17
The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.
Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them 17.11.2026 19:18
They discuss Roivant's structure and programs (a top holding of Affinity's) and how different investors view companies different ways. Plus, the ups and downs of biotech, and why it is rare for smaller biotech companies to grow into larger entities over the long run.
Jefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces 17.11.2026 14:10
He shares an update on the ulixacaltamide and relutrigine filings, and how he thinks about potential commercialization opportunities. Plus, late stage readouts to watch out for.
Jefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA 17.11.2026 16:44
He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.
Jefferies London 2026: Protagonist Therapeutics' CEO Dinesh Patel discusses the launch of ICOTYDE, and the company's pipeline, which is well funded now due to commercial success 17.11.2026 11:22
He comments on the early days of JNJ's ICOTYDE launch, developing an optimized IL-17, the obesity space, and more.
Jefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects 17.11.2026 12:37
He discusses the regulatory status of Lyme disease, which hit on secondary enpoints in its phase three trial but narrowly missed the primary. Plus, updates on chikungunya and shigella.
Jefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more 16.11.2026 10:03
He describes the win-win nature of working with Anthropic, which is related to redesigning CAR T-Cell Signaling. Plus, he discusses room for improvement in the TSLP space and why he believes Generate's candidate could be best in class.
Jefferies London 2026: Nuvation Bio Founder & CEO David Hung shares an update on the launch of IBTROZI (next-gen ROS1 inhibitor and follow-on pipeline projects 16.11.2026 9:36
He discusses the launch and his thoughts on any future copetitors in the space. Plus an update on the mIDH1 inhibitor safusidenib, and a drug-drug interaction platform that was the basis for founding the company.
Jefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema 16.11.2026 9:34
President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program.
Jefferies 2026: Nektar Therapeutics has Rezpeg moving full speed ahead in atopic dermatitis and alopecia (and beyond) - the Head of R&D shares learnings about its mechanism 16.11.2026 11:17
Jonathan Zalevsky describes how learnings from the phase 2 AD trial have helped with the study design of three phase 3 studies - and the latest on alopecia. He emphasizes how the company seems to be seeing a deepening of responses from this Treg targeting mechanism over time.
Jefferies 2026: Sofinnova Partners announced today a new $815M fund today that will invest in mostly later stage European companies 16.11.2026 10:56
Managing Partner Graziano Seghezzi tells us about the new fund and what it will invest in, and comments on the environment for European biotech today.
Jefferies London: While its in the middle of the closely watched Attruby launch, BridgeBio has two other medicines in front of FDA and another big phase 3 readout scheduled for later next year 16.11.2026 9:34
Founder & CEO Neil Kumar shares his take on how the Attruby launch is going, and also talks Limb-girdle muscular dystrophy type 2I/R9, achondroplasia, and hypoparathyroidism.
STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors 12.11.2026 8:21
Co-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of its antisense oligonucleotide that aims to restore expression, and also concurrently an investigator led study in China.
STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in phase 2 studies compared to existing products and could be dosed as little as once or twice a year - a key update will read next month 12.11.2026 11:13
CEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December. Plus, how the company is thinking about phase 3 design, and other assets in the pipeline.
Stifel's Tim Opler on the state of biotech 11.11.2026 9:48
Ahead of a 100+ slide "State of Biotech" report he is publishing tomorrow, he discusses the impact of Washington on biotech, how the sector has been trading lately, China, M&A and a lot more
STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months 11.11.2026 18:39
CEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen with other Alzheimer's treatments and discusses what the company hopes to see from this phase 1b study. Plus, comments on the recent failure of another company in this space.
STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial in human data on its oral PTH19 agonist for hypoparathyroidism in Q1 11.11.2026 9:14
Co-Founder & CEO Jeff Finer walks us through the company's GPCR discovery platform, and discusses, this lead program, a new target (TSHR) they just named in Grave's disease and thyroid eye disease, and the company's work in obeisty with partner Novo Nordisk.
STIFEL 2026: Rapport Therapeutics' CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead 11.11.2026 8:09
He describes the company's precision mechanism, and discussions they will have with FDA before starting phase 3 trials in this indicuation next year. Plus, previewing long-term data that will be out soon in epilepsy.
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.